Bullfrog AI highlights 2023 achievements: $8.4M IPO, first revenue, key partnerships

BullFrog AI Holdings, Inc.

Completed $8.4M IPO listing on Nasdaq in 2023; maintained low burn rate quarter to quarter.
Recorded first earned revenue in Q3 2023; transition to commercial operations.
Entered exclusive partnership with Lieber Institute for Brain Development for neuropsychiatric drug discovery.
Demonstrated efficacy of oncology drug candidates BF-223 and BF-222 in glioblastoma animal model; patent issued for BF-223.
Identified three novel colorectal cancer targets via JCVI partnership; market $11.5B in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.